Close Menu

financial guidance

The company's life sciences revenues were up 6 percent while its diagnostics business grew almost 7 percent.

The company delivered organic growth across its four business segments and raised its revenue and earnings guidance for the year.

Within Diagnostics, year-over-year core laboratory Q3 revenues rose 8 percent to $1.18 billion but molecular diagnostics revenues fell 8 percent to $111 million.

Qiagen will develop IVDs for use on Illumina's clinical sequencers and reported preliminary Q3 revenue growth of 3 percent at a constant exchange rate.

The Belgian oncology molecular diagnostics firm reported a 17 percent increase in product sales but said that sales of cartridges in the US were lower than expected. 

The index, which slightly underperformed the Dow Jones, had a smaller loss in August than in the previous month.

The firm's diagnostics and genomics group saw an 11 percent year-over-year revenue increase in the third quarter.

The company beat analyst estimates on the top and bottom line, driven by sales of its Panorama noninvasive prenatal and Horizon carrier screening tests.

The company sold nearly twice as many tests as in Q2 last year, with clinical test revenue more than doubling and total revenue reaching $54 million for the quarter.

The firm reported revenues of $13.6 million and raised full-year revenue guidance, but revised full-year earnings guidance downward.

Pages

The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.

The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.

The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.

In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.